Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Dr. Mason on Standard Treatment Approaches in Stage III NSCLC

April 23rd 2019

David P. Mason, MD, chief of thoracic surgery and lung transplantation, Baylor Scott & White Healthcare System, chief of lung transplantation, Baylor University Medical Center, discusses standard treatment approaches available for patients with stage III non–small cell lung cancer (NSCLC).

Dr. Konduri on Sequencing Therapy in EGFR+ NSCLC

April 18th 2019

Kartik Konduri, MD, co-medical director of the Lung Cancer Center of Excellence, Baylor Charles A. Sammons Cancer Center, on the campus of Baylor University Medical Center, discusses sequencing therapy in patients with EGFR-positive non–small cell lung cancer.

Dr. Mansfield Discusses Challenges in SCLC

April 18th 2019

Aaron S. Mansfield, MD, associate professor of oncology, consultant in the Division of Medical Oncology, Mayo Clinic, discusses challenges in the treatment of patients with small cell lung cancer.

Amid Advances, Obstacles Remain in Small Cell Lung Cancer

April 17th 2019

Aaron S. Mansfield, MD, discusses recent progress in small cell lung cancer and remaining challenges in the field.

Durvalumab Results Spark Hope for Progress in Advanced NSCLC

April 16th 2019

During an OncLive Peer Exchange® discussion, moderator Mark A. Socinski, MD, and other lung cancer experts from across the United States discuss what, in this context, the PACIFIC trial results mean for practicing oncologists and their patients.

Dr. Socinski on New Applications of Immunotherapy in NSCLC

April 16th 2019

Mark A. Socinski, MD, executive medical director, AdventHealth Medical Group, discusses new applications for immunotherapy in the treatment of patients with non–small cell lung cancer.

Atezolizumab Regimen Improves OS After TKI Failure in EGFR+ NSCLC

April 14th 2019

Atezolizumab plus bevacizumab, carboplatin, and paclitaxel has emerged as a potential new standard of care for patients with EGFR-positive metastatic nonsquamous non–small cell lung cancer who have failed prior TKIs.

Dr. Reinmuth on Findings from the MYSTIC Study

April 13th 2019

Niels Reinmuth, MD, PhD, discusses the results of the MYSTIC study, which evaluated first-line durvalumab plus tremelimumab versus platinum-based chemotherapy in patients with metastatic non–small cell lung cancer.

Dr. Yang on Osimertinib as First-Line Therapy for EGFR-Positive NSCLC

April 13th 2019

James Chih-Hsin Yang, MD, discusses the final safety and efficacy results from 2 phase I expansion cohorts from the phase I/II AURA trial.

Mok Provides Pembrolizumab Update, Next Steps With Immunotherapy in NSCLC

April 13th 2019

Tony Mok, MD, discusses the KEYNOTE-042 trial and the implications of its findings, and sheds light on the evolving role of immunotherapy in non–small cell lung cancer.

Nivolumab/Ipilimumab Falls Short as Maintenance Therapy in SCLC

April 13th 2019

No overall survival advantage was obtained from maintenance therapy comprising nivolumab (Opdivo) alone or in combination with ipilimumab (Yervoy) over placebo in patients with extensive-stage small cell lung cancer.

Ramalingam Discusses Osimertinib Efficacy and the Journey to Overcome Acquired Resistance

April 12th 2019

Suresh S. Ramalingam, MD, describes findings with osimertinib, and discusses the emerging body of data exploring primary and acquired resistance mechanisms to the third-generation agent.

Update Further Supports Osimertinib in Frontline EGFR+ NSCLC

April 12th 2019

Final results from 2 phase I expansion cohorts of frontline osimertinib (Tagrisso) presented at the 2019 European Lung Cancer Congress confirmed the efficacy of the third-generation TKI in patients with EGFR-positive non–small cell lung cancer.

Dr. Reck on the Rationale of the Impower150 Study

April 12th 2019

Martin Reck, MD, PhD, head of the department of thoracic oncology at Lung Clinic Grosshansdorf, discusses the rationale for the IMpower150 study.

Dr. Paz-Ares on Entrectinib in NTRK Fusion-Positive NSCLC

April 12th 2019

Luis G. Paz-Ares, MD, PhD, chief physician at the Hospital Universitario Doce De Octubre, discusses an integrated analysis of patients with NTRK fusion–positive non–small-cell lung cancer enrolled in the STARTRK-2, STARTRK-1, and ALKA-372-001 trials, which evaluated the safety and efficacy of entrectinib in patients with solid tumors.

Dr. Farago on the FDA Approval of Pembrolizumab for Lower PD-1 Cutoff NSCLC

April 12th 2019

Anna F. Farago, MD, PhD, assistant professor of medicine at Harvard Medical School, discusses the FDA approval of single-agent pembrolizumab for the frontline treatment of patients with stage III non–small cell lung cancer, who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score) level of ≥1% and do not harbor EGFR or ALK aberrations.

FDA Lowers Pembrolizumab PD-L1 Cutoff in NSCLC, Expands Approval to Stage III

April 12th 2019

The FDA has expanded the approval for pembrolizumab monotherapy for the frontline treatment of patients with stage III non–small cell lung cancer, who are ineligible for surgery or definitive chemoradiation, or metastatic NSCLC, with a PD-L1 expression (tumor proportion score) level of ≥1% and do not harbor EGFR or ALK aberrations.

Entrectinib Data Highlighted as FDA Weighs Approval for ROS1+ NSCLC

April 12th 2019

Patients with ROS1-positive non–small cell lung cancer showed high response rates and durable responses following treatment with entrectinib.

PD-L1 Expression Does Not Impact QoL With Durvalumab in NSCLC

April 11th 2019

Patient reported outcomes according to PD-L1 expression did not show clinically meaningful differences in quality of life with either durvalumab or placebo in patients with stage III non–small cell lung cancer, according to a retrospective analysis of the phase III PACIFIC study.

Subsequent Immunotherapy in Control Arm Confounds Frontline Durvalumab Data in NSCLC

April 11th 2019

The initial overall survival analysis of the phase III MYSTIC trial of first-line durvalumab (Imfinzi) alone or in combination with tremelimumab compared with platinum-based chemotherapy in patients with metastatic non–small cell lung cancer, may have been confounded by high rates of post-study immunotherapy given in the control arm.